| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/26/2002 | US20020136740 With an antigen that has an epitope of hepatitis c virus |
| 09/26/2002 | US20020136739 Subunit respiratory syncytial virus preparation |
| 09/26/2002 | US20020136738 Growing mycobacterium in the allogeneic and syngeneic macrophages and cell lines and irradiating |
| 09/26/2002 | US20020136737 Isolated nucleic acids comprising Listeria dal and dat genes |
| 09/26/2002 | US20020136736 Or prophylactically or therapeutically effective fragment thereof in admixture with a pharmaceutically acceptable carrier |
| 09/26/2002 | US20020136735 Preparations that potentiate immunogenicity in low immunogenic antigens |
| 09/26/2002 | US20020136734 Vaccines for the protection of cattle from psoroptic scabies |
| 09/26/2002 | US20020136733 From Plasmodium falciparum antigens, circumsporozoite protein, thrombospondin-related anonymous protein,spirozoite hepatocyte binding antigen,liver-stage antigen-1; cytotoxic T lymphocyte epitopes for human leucocyte antigens; malaria vaccine |
| 09/26/2002 | US20020136730 From coagulase-negative bacteria produced in substantially pure form; use of purified adhesin product as vaccine for production of antibodies effective against binding of homologous bacterial cells to polymeric materials |
| 09/26/2002 | US20020136729 Combined physical and immunotherapy for cancer |
| 09/26/2002 | US20020136727 Immunogen adherence inhibitor and method of making and using same |
| 09/26/2002 | US20020136726 Method for selectively delivering agent to arterial smooth muscle cells in mammal comprising administering agent and substance which selectively binds arterial smooth muscle cell-specific surface molecule selected from ephrin family |
| 09/26/2002 | US20020136725 Administering monoclonal antibodies that bind to a human coagulation factor or cofactor for use as self-limiting inhibitors of thrombosis in combination with plasminogen activators |
| 09/26/2002 | US20020136724 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 09/26/2002 | US20020136723 Administering methotrexate and an anti-tumor necrosis factor antibody or fragment thereof; rheumatoid arthritis, Crohn's disease, acute and chronic immune diseases |
| 09/26/2002 | US20020136722 Adjuvants comprising CD40 ligands crosslinked to antigens, wherein the adjuvants have reduced toxicity and adjuvants comprising CD40 ligands crosslinked to viral antigens |
| 09/26/2002 | US20020136720 Methods of using IMXP-888 and IMXP-888 antagonists |
| 09/26/2002 | US20020136719 For biomedical applications, including biological delivery to humans and animals |
| 09/26/2002 | US20020136718 Using antibody which catalyzes hydrolysis of beta-amyloid at a predetermined amide linkage |
| 09/26/2002 | US20020136715 Composition comprising a binding agent that specifically binds to circulating prostate specific antigen and induces a therapeutic immune response |
| 09/26/2002 | US20020136704 Method for determining susceptibility of thymus in patient to activation through disruption of sex steroid signaling to thymus |
| 09/26/2002 | US20020136695 Human medical treatment by aerosol inhalation of immunoglobulin A |
| 09/26/2002 | US20020136689 Antibody which specifically binds to prostate stem cell antigen on surface of carcinoma cells and is internalized within carcinoma cells to which it binds |
| 09/26/2002 | US20020135085 Production scale method of forming microparticles |
| 09/26/2002 | CA2852293A1 Attenuated pasteurellaceae bacteria and an anti-bacterial vaccine prepared therefrom |
| 09/26/2002 | CA2460779A1 Use of gram-negative bacterial membrane fraction for inducing the maturation of dendritic cells |
| 09/26/2002 | CA2445486A1 Patch for transcutaneous immunization |
| 09/26/2002 | CA2441530A1 Transcutaneous immunostimulation |
| 09/26/2002 | CA2441147A1 Methods of treating disorders of the eye and surrounding tissue with thymosin .beta.4 (t.beta.4), analogues, isoforms and other derivatives |
| 09/26/2002 | CA2441095A1 Modified interferon beta with reduced immunogenicity |
| 09/26/2002 | CA2441057A1 Polyclonal populations of bispecific molecules and methods of production and uses thereof |
| 09/26/2002 | CA2441042A1 Monoclonal antibody therapy for pancreas cancer |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2439530A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 09/26/2002 | CA2438942A1 Influenza vaccine formulations for intradermal delivery |
| 09/26/2002 | CA2438315A1 Attenuated pasteurellaceae bacteria and an anti-bacterial vaccine prepared therefrom |
| 09/26/2002 | CA2438279A1 Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| 09/26/2002 | CA2435664A1 Ncc2705-the genome of a bifidobacterium |
| 09/26/2002 | CA2435000A1 Oligomeric complexes of chimeric proteins with enhanced immunogenic potential |
| 09/25/2002 | EP1243655A1 Modified HPV E6 and E7 genes and proteins useful for vaccination |
| 09/25/2002 | EP1243652A2 Glial derived neurotrophic factor |
| 09/25/2002 | EP1243650A2 Process for constructing a cdna library, and a polypeptide and dna coding for the same |
| 09/25/2002 | EP1243597A2 Receptors for human interleukin-12 |
| 09/25/2002 | EP1243273A1 Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters |
| 09/25/2002 | EP1243256A1 Vaccines absorbable by the transmucosal way |
| 09/25/2002 | EP1242823A2 Selecting library members capable of binding to epitopes |
| 09/25/2002 | EP1242617A2 Method of classifying a thyroid carcinoma using differential gene expression |
| 09/25/2002 | EP1242611A2 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 09/25/2002 | EP1242609A2 Novel colloid synthetic vectors for gene therapy |
| 09/25/2002 | EP1242600A1 Cytokine zcyto18 |
| 09/25/2002 | EP1242598A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242576A1 Stabilizing diluent for polypeptides and antigens |
| 09/25/2002 | EP1242458A2 Brain specific binding members |
| 09/25/2002 | EP1242457A1 Intrabodies with defined framework that is stable in a reducing environment and applications thereof |
| 09/25/2002 | EP1242456A2 Scfv antibodies against disease associated molecules |
| 09/25/2002 | EP1242446A1 Immunoenzymatic quantification method |
| 09/25/2002 | EP1242441A2 Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |
| 09/25/2002 | EP1242365A1 Acyl pseudodipeptides which carry a functionalised auxiliary arm |
| 09/25/2002 | EP1242124A1 Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
| 09/25/2002 | EP1242122A2 Delivery of proteins across polar epithelial cell layers |
| 09/25/2002 | EP1242118A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 09/25/2002 | EP1242117A1 Method for treatment of canine distemper |
| 09/25/2002 | EP1242115A1 Chemically-programmable immunity |
| 09/25/2002 | EP1242108A1 Optimized minigenes and peptides encoded thereby |
| 09/25/2002 | EP1242060A1 Treatment of metastatic disease |
| 09/25/2002 | EP1242049A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 09/25/2002 | EP1241945A2 Cancer immunotherapy and diagnosis using cytochrome p450 1b1 |
| 09/25/2002 | EP0918540B1 Intradermal bovine polynucleotide vaccine |
| 09/25/2002 | EP0652966B1 Method of increasing expression of viral proteins |
| 09/25/2002 | CN1371416A Human CTLA-4 antibodies and their uses |
| 09/25/2002 | CN1371389A 疫苗 Vaccine |
| 09/25/2002 | CN1371286A Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia |
| 09/25/2002 | CN1371285A Methods and compounds for treatment of immunologically-mediated diseases using mycobacterium vaccae |
| 09/25/2002 | CN1370601A Prepn of single-component slowly released genetically engineered hepatitis B vaccine microballoon |
| 09/25/2002 | CN1370575A Composite prepn for preventing and treating young animal's darrhea and its prepn process |
| 09/24/2002 | US6455686 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 09/24/2002 | US6455674 Polypeptide for use in the diagnosis and treatment of tissue oxygenation defects |
| 09/24/2002 | US6455673 Polypeptide for use as vaccine in prevention of microorganismal infections |
| 09/24/2002 | US6455668 Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| 09/24/2002 | US6455574 Administering a combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof for treatment of combined hypertension and hyperlipidemia |
| 09/24/2002 | US6455503 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| 09/24/2002 | US6455492 Hepatitis E virus vaccine and method |
| 09/24/2002 | US6455323 Contacting virulence protein with chemical compound, then identifying compounds which bind or interacts with protein; for bactericides against staphylococcus aureus |
| 09/24/2002 | US6455299 Methods of use of viral vectors to deliver antigen to dendritic cells |
| 09/24/2002 | US6455298 Animal cells and processes for the replication of influenza viruses |
| 09/24/2002 | US6455290 Tankyrase homolog protein (THP), nucleic acids, and methods related to the same |
| 09/24/2002 | US6455278 Nucleic acid which encodes protein of defined amino acid sequence involved in pain perception; analgesics |
| 09/24/2002 | US6455277 Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides |
| 09/24/2002 | US6455267 Methods and kits useful for determining the status of and detecting pancreatic B-cell associated autoimmune diseases |
| 09/24/2002 | US6455265 Preparing candidate immunogenic agents based on an envelope protein of a pathogenic strain, then selecting a modified polypeptide which induces an immune response against the immunodomnant region of the protein but not the host |
| 09/24/2002 | US6455245 For immunoassay detection |
| 09/24/2002 | US6455244 Methods for the detection of antibodies associated with autoimmune disorders and infectious agents employing immunoretroid peptides derived from antigens associated with said disorders and agents |
| 09/24/2002 | US6455074 Methods of forming and using the device for the sustained release of an active agent. the improved method of the invention for forming a polymer-based sustained release device comprises forming a polymer/active agent solution by mixing a |
| 09/24/2002 | US6455050 Human administration comprising a protective, highly-immunogenic, non-immunopotentiating copurified mixture of hn and f glycoproteins of human parainfluenza type 3 prepared by copurification from native piv-3 virus by affinity |
| 09/24/2002 | US6455049 Biologically active and particularly peptide molecules having a potentiating effect on growth hormone biological activity |
| 09/24/2002 | US6455048 Immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. administering a complex of heat shock protein |
| 09/24/2002 | US6455047 Methods to improve immunogenicity of antigens and specificity of antibodies |
| 09/24/2002 | US6455046 Use of mCRP to enhance immune responses |